LCTX - Lineage Cell Therapeutics Inc Stock Price, Fair Value and News

1.01USD-0.03 (-2.88%)Market Closed

Market Summary

USD1.01-0.03

Market Closed

-2.88%

LCTX Stock Price

View Fullscreen

LCTX RSI Chart

LCTX Valuation

Market Cap

190.7M

Price/Earnings (Trailing)

-8.06

Price/Sales (Trailing)

23.83

EV/EBITDA

-6.33

Price/Free Cashflow

-8.07

LCTX Price/Sales (Trailing)

LCTX Profitability

Operating Margin

91.88%

EBT Margin

-295.30%

Return on Equity

-32.67%

Return on Assets

-21.81%

Free Cashflow Yield

-12.39%

LCTX Fundamentals

LCTX Revenue

Revenue (TTM)

8.0M

Rev. Growth (Yr)

-39.48%

Rev. Growth (Qtr)

-30.84%

LCTX Earnings

Earnings (TTM)

-23.7M

Earnings Growth (Yr)

-49.63%

Earnings Growth (Qtr)

-37.01%

Breaking Down LCTX Revenue

Last 7 days

2.0%

Last 30 days

13.2%

Last 90 days

-9.6%

Trailing 12 Months

-26.4%

How does LCTX drawdown profile look like?

LCTX Financial Health

Current Ratio

2.71

LCTX Investor Care

Shares Dilution (1Y)

10.94%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.0M	0	0	0
2023	11.9M	10.5M	8.8M	8.9M
2022	5.6M	10.1M	13.0M	14.7M
2021	666.0K	684.0K	751.0K	445.0K
2020	678.0K	0	0	0
2019	545.0K	322.0K	256.0K	257.0K
2018	2.3M	2.3M	691.0K	691.0K
2017	4.9M	3.8M	2.8M	1.8M
2016	7.0M	6.5M	6.1M	5.9M
2015	4.5M	5.4M	6.3M	5.9M
2014	4.1M	4.0M	4.4M	4.4M
2013	3.3M	3.4M	3.0M	3.6M
2012	4.2M	4.4M	4.0M	3.5M
2011	3.8M	3.8M	4.2M	4.4M
2010	0	2.5M	3.1M	3.7M
2009	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

CEO	Mr. Brian M. Culley M.A., M.B.A.
WEBSITE	https://lineagecell.com
INDUSTRY	Biotechnology
EMPLOYEES	70

Lineage Cell Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Lineage Cell Therapeutics Inc? What does LCTX stand for in stocks?

LCTX is the stock ticker symbol of Lineage Cell Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lineage Cell Therapeutics Inc (LCTX)?

As of Thu Jul 25 2024, market cap of Lineage Cell Therapeutics Inc is 196.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LCTX stock?

You can check LCTX's fair value in chart for subscribers.

Is Lineage Cell Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LCTX is over valued or under valued. Whether Lineage Cell Therapeutics Inc is cheap or expensive depends on the assumptions which impact Lineage Cell Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LCTX.

What is Lineage Cell Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, LCTX's PE ratio (Price to Earnings) is -8.3 and Price to Sales (PS) ratio is 24.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LCTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lineage Cell Therapeutics Inc's stock?

In the past 10 years, Lineage Cell Therapeutics Inc has provided -0.075 (multiply by 100 for percentage) rate of return.